Lisinopril Dihydrate: Precision Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate (SKU B3290) is a commercially available, long-acting ACE inhibitor with an IC₅₀ of 4.7 nM, used extensively in hypertension and cardiovascular research (APExBIO). Its mechanism centers on the inhibition of angiotensin converting enzyme (EC 3.4.15.1), reducing angiotensin II and aldosterone levels, and increasing plasma renin, thus lowering blood pressure through vasodilation and decreased fluid retention (Tieku & Hooper 1992). Lisinopril dihydrate is a lysine analogue of MK 421, supplied by APExBIO at ≥98% purity, and is soluble in water (≥2.46 mg/mL with warming/ultrasound), but insoluble in ethanol. Benchmarks confirm its selectivity for ACE over related metallopeptidases, enabling precise studies of the renin-angiotensin system. This article details its biological rationale, mechanism, evidence, experimental integration, and common limitations with stable citations and structured data.

Biological Rationale

The renin-angiotensin system (RAS) is a central regulator of blood pressure, fluid balance, and electrolyte homeostasis. Angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. Elevated angiotensin II levels contribute to hypertension, heart failure, and renal pathologies. Inhibiting ACE disrupts this pathway, leading to vasodilation, decreased aldosterone secretion, and reduced blood pressure (Tieku & Hooper 1992).

Lisinopril dihydrate is a synthetic lysine derivative that selectively inhibits ACE. Its long-acting profile and high specificity make it a preferred tool for dissecting RAS signaling in preclinical models of hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy (Lisinopril Dihydrate: Precision ACE Inhibitor—this article extends prior guidance by detailing molecular benchmarks and storage conditions).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate binds to the active site of ACE, preventing the cleavage of angiotensin I to angiotensin II. The IC₅₀ value for ACE inhibition is 4.7 nM, demonstrating high potency under in vitro conditions (37°C, pH 7.4, buffer: 50 mM Tris-HCl) (Tieku & Hooper 1992). This inhibition is competitive and reversible. As a result, plasma angiotensin II and aldosterone decrease, while plasma renin activity increases due to feedback mechanisms.

Lisinopril dihydrate does not significantly inhibit related cell-surface zinc aminopeptidases, such as aminopeptidase A (AP-A), aminopeptidase N (AP-N), or aminopeptidase W (AP-W), supporting its target selectivity. Its chemical structure (C₂₁H₃₅N₃O₇·2H₂O) incorporates a lysine side chain, differentiating it from earlier ACE inhibitors and conferring improved pharmacokinetic stability.

Evidence & Benchmarks

• Lisinopril dihydrate exhibits an IC₅₀ of 4.7 nM for ACE inhibition, measured in standardized enzyme assays (Tieku & Hooper 1992, DOI).
• It does not inhibit AP-A, AP-N, or AP-W at concentrations up to 100 μM, confirming specificity for ACE (Tieku & Hooper 1992, DOI).
• Solubility in water is ≥2.46 mg/mL with gentle warming (up to 37°C) and ultrasonic treatment; insoluble in ethanol (APExBIO).
• Purity is ≥98% by HPLC, confirmed by mass spectrometry and NMR (Certificate of Analysis, APExBIO).
• Storage at room temperature in a desiccated state preserves chemical stability for ≥12 months; solutions are not recommended for long-term storage (Vendor data, APExBIO).

For expanded comparative analysis of workflow parameters, see Lisinopril dihydrate (SKU B3290): Reliable ACE Inhibition, which this article augments by providing peer-reviewed selectivity benchmarks.

Applications, Limits & Misconceptions

Lisinopril dihydrate is widely used in preclinical models to dissect the renin-angiotensin pathway, study blood pressure regulation, and assess outcomes in hypertension, heart failure, myocardial infarction, and diabetic nephropathy (Lisinopril Dihydrate (SKU B3290): Reliable ACE Inhibition). Compared to other ACE inhibitors, its aqueous solubility and purity support high-reproducibility cell culture and animal studies. However, it is ineffective in models where RAS is not the dominant pathway or when off-target peptidase inhibition is required.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate does not inhibit aminopeptidase A, N, or W: Targeting these enzymes requires different inhibitors (Tieku & Hooper 1992).
• Not effective for ACE-independent hypertension: Models driven by non-RAS mechanisms will not respond.
• Solubility limitations in non-aqueous solvents: Insoluble in ethanol; always dissolve in water with warming/ultrasonication (APExBIO).
• Long-term solution storage not recommended: Chemical stability drops in solution; prepare fresh aliquots for each experiment.
• No direct anti-inflammatory or anti-metastatic effects: Its action is limited to ACE inhibition, not general peptidase or immune targets.

Workflow Integration & Parameters

Lisinopril dihydrate is supplied by APExBIO as a solid powder (molecular weight: 441.52 g/mol). For experimental use, dissolve in ultrapure water at concentrations ≥2.46 mg/mL with gentle warming (≤37°C) and ultrasonication. Avoid ethanol as a solvent. Prepare fresh solutions immediately before use to maximize stability. Store the dry powder in a desiccated container at room temperature; do not freeze.

For cell-based assays, typical working concentrations range from 0.01 to 10 μM, depending on model and endpoint. In vivo studies often employ 0.1–10 mg/kg dosing regimens, with adjustments based on pharmacokinetic modeling. Shipping is performed on blue ice to preserve integrity. Quality is verified by HPLC, mass spectrometry, and NMR. The product page (Lisinopril dihydrate) provides certificates of analysis and batch-specific documentation.

For protocols and troubleshooting, see Lisinopril Dihydrate: Precision ACE Inhibitor for Hypertension Models, which this article updates with current purity, solubility, and mechanistic selectivity data.

Conclusion & Outlook

Lisinopril dihydrate, as provided by APExBIO, is a validated, long-acting ACE inhibitor with high specificity, purity, and aqueous solubility. It is a cornerstone reagent for hypertension, heart failure, and nephropathy research, enabling mechanistic dissection of the renin-angiotensin system. Stringent quality controls and clearly defined solubility/storage protocols ensure reproducible data. Researchers should select Lisinopril dihydrate when high selectivity for ACE and robust, reproducible experimental outcomes are required.